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IZVLEEK
Proteinski ﬁbrili nastanejo z agregacijo delno zvitih proteinov in so odgovorni ali
pomembno vplivajo na mnogo hudih £love²kih bolezni, kot sta Alzeimerjeva ali di-
abetes tipa II. Samo-replikacija ﬁbrilov je proces, v katerem obstoje£i proteinski
ﬁbrili katalizirajo nastanek novih ﬁbrilov na na£in, da ponudijo vezavno povr²ino,
kjer se proteini laºje sre£ajo in agregirajo. To prispeva k naglem in eksponent-
nem napredovanju bolezni. V magistrski nalogi predstavimo Monte Carlo simulacije
ra£unalni²kega modela agregacije, v katerega vpeljemo inhibitorje. To so delci, ki
se lahko veºejo na povr²ino ﬁbrilov in tako inhibirajo oziroma upo£asnijo proces
samo-replikacije. Tak²en na£in inhibicije se izkaºe za zelo u£inkovit, ampak zaradi
odbojne interakcije med delci naletimo tudi na pojav makromolekularnega gne£enja,
ki povzro£i, da se pri dolo£eni pokritosti povr²ine s proteini hitrost samo-replikacije
pove£a. Edinstven deskriptor hitrosti replikacije najdemo v povpre£ni velikosti
skupka na povr²ino vezanih proteinov, ki nosi informacijo o celotni porazdelitvi
agregacijskih skupkov. Predstavimo teorije, ki uspe²no razloºijo vse zna£ilnosti
opaºanega obna²anja. S pomo£jo mreºnega modela napovemo, katere interakcije
med delci na povr²ini imajo najve£ji inhibicijski potencial.
Klju£ne besede: agregacija amiloidov, samo-sestavljanje proteinov, inhibicija, ra£u-
nalni²ke simulacije, metoda Monte Carlo, nukleacijski mehanizem, gne£enje makro-
molekul, krajina proste energije, statisti£na mehanika, mehka snov, ﬁzikalna kemija
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ABSTRACT
Protein ﬁbrils are formed by a process called amyloid aggregation and are impli-
cated in many debilitating human diseases such as Alzheimer's or Type II Diabetes.
Self-replication of ﬁbrils is a process by which existing protein ﬁbrils catalyse the
formation of new ﬁbrils by oﬀering a surface on which proteins can bind, and there-
fore facilitate aggregation. This leads to exponential growth of ﬁbril mass and fast
propagation of amyloid diseases. In this thesis, we present simulations of a minimal
but fairly complex computational model of aggregation with added inhibitory par-
ticles that can bind to the ﬁbril surface. It turns out the mechanism of inhibition
where inhibitors compete with proteins for the surface is very promising. However,
we also ﬁnd a manifestation of a macromolecular crowding eﬀect which actually
promotes self-replication at given protein coverage of the ﬁbril surface. We ﬁnd a
unique descriptor for the rate of replication in the average protein aggregate size. We
present theories that successfully explain all characteristics of observed simulation
behaviour. By employing a lattice model, we predict which inter-particle interac-
tions on the ﬁbril surface have the largest inhibitory potential.
Key words: Amyloid Aggregation, Self-assembly, Protein Fibrils, Inhibition, Course-
grained Simulation, Monte Carlo Method, Nucleation Mechanism, Macromolecu-
lar Crowding, Free Energy Landscape, Statistical Mechanics, Soft Matter, Physical
Chemistry
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1 Introduction
Amyloid ﬁbrils are a form of protein assembly that results from the aggregation
of normally soluble proteins. Fibrils are elongated thread-like structures and are a
dominant type of protein aggregate that is associated with more than 50 increasingly
prevalent human diseases which are at present incurable [1, 2]. All these diseases
share a common morphology even though the soluble proteins that make up the
aggregates as well as the area of pathogenic inﬂuence vary substantially across dis-
eases. Diseases most associated with amyloid aggregation are Parkinson's disease
with its α-synuclein protein, Diabetes II with amylin, various types of Amyloidosis,
and chieﬂy Alzheimer's disease with its Aβ peptide which accounts for up to 80%
of all dementia cases [3].
The aggregation reaction ordinarily involves many molecular steps [1, 47]. A
ﬁrst important step is spontaneous or primary nucleation by which the ﬁrst ﬁbril
nuclei are formed from soluble monomers in solution. These nuclei then grow by
an attachment of monomeric proteins to ﬁbril ends by a process called elongation,
eventually into mature ﬁbrils that are observable under the microscope. These two
processes are enough to explain the early time signature of the aggregation reaction.
But recent experiments revealed that once ﬁrst amyloid ﬁbrils are generated, their
surfaces catalyse the formation of new ﬁbril nuclei via a secondary self-replication
process, which leads to exponential growth of ﬁbril mass and therefore to fast prop-
agation of amyloid diseases [5, 812].
Particularly in Alzheimer's disease, this secondary auto-catalytic process has
been found to be the main source of new ﬁbril nuclei [8,9,13,14]. Even more impor-
tantly, it is a dominant source of oligomers, intermediate protein aggregates that do
not yet posses the a β-sheet structure characteristic of mature ﬁbrils but are able to
convert to a growth-competent ﬁbril nucleus. These intermediate species are impor-
tant as it has been found that fully grown protein ﬁbrils do not signiﬁcantly interact
with the mammal brain as previously believed and are quite inert. Oligomers, in
fact, have been found to be toxic to neuronal cells and are now believed to be the
main cause of neuronal death in Alzheimer's patients [1].
In order to slow down or eliminate the self-replication process that generates the
majority of toxic oligomers, we can try to cover the binding sites on the catalytic
ﬁbril surface. Recent experiments with Alzheimer's Aβ aggregation have revealed
an inhibitory particle, a type of chaperone, that non-selectively binds to the ﬁbril
surface and in eﬀect signiﬁcantly slows down the self-replication process both in
vitro and in vivo [13, 1522]. The molecular mechanism of inhibition, however, has
not yet been suﬃciently explored and will form the subject of this master's thesis.
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The aggregation reaction is by its nature very rapid, heterogeneous, and in-
volves several molecular steps. Just developing an experimental protocol for getting
reproducible kinetic data on the time dependence of ﬁbril mass has been a break-
through in the ﬁeld of amyloid disease. It is therefore no wonder that the exact
molecular mechanisms driving primary spontaneous nucleation, elongation, or self-
replication remain hardly accessible to experimental analysis of macroscopic data.
This is where computer simulations come of use. Computational models along with
theoretical reasoning can provide a window to the behaviour of aggregation reac-
tions on a molecular scale. In silico, one can isolate individual molecular steps of
the aggregation reaction and utilise simple models that successfully reproduce and
subsequently also interpret experimental ﬁndings [2330]. In order to investigate
the inhibition mechanism for thwarting self-replication, we will therefore build upon
a computational model that has already been used to characterise the mechanism
of self-replication [24] and upgrade the model by incorporating inhibitory particles.
In section 2 we will discuss in detail the course-grained computational model
that we use to investigate the secondary nucleation mechanism as well as its inhi-
bition. In 2.1 we discuss the main characteristics of our course-grained model for
amyloid aggregation and then speciﬁcally focus on the interactions between vari-
ous particles in 2.1.1, the choice of interaction parameters in 2.1.2, and ﬁnally our
setup for the Monte Carlo simulation in 2.1.3. We then discuss the results of our
simulations in section 3. First, we discuss the nucleation mechanism and behaviour
in the absence of inhibitors in section 3.1. To test the code, we attempt and suc-
ceed at reproducing some of the results of a previous study [24] in the limit of no
inhibitor particles (section 3.1.1). We then perform many additional simulations
at previously unexplored external simulated conditions that provide novel insights
into the nucleation mechanism (section 3.1.2). Especially, we provide further ev-
idence that the ﬁbril surface coverage by monomeric proteins determines the rate
of nucleation. Additionally, we identify the most important structural steps in the
nucleation pathway and discuss which of those steps are rate-determining. Next we
perform extensive simulations with inhibitors that are capable to bind to the ﬁbril
surface in section 3.2. As hypothesized, we ﬁnd that the surface-bound inhibitors
reduce the rate of nucleation. We then look at the binding isotherms of both protein
particles and inhibitors and ﬁnd the binding to be non-ideal (section 3.2.1). Then, by
plotting the rate of nucleation against monomer coverage, we interestingly ﬁnd that
inhibitors perturb the nucleation mechanism by crowding the ﬁbril surface (section
3.2.2) and that monomer coverage does not uniquely determine the nucleation rate.
We successfully account for this crowding eﬀect by acknowledging that inhibitors
reduce the free energy of oligomerisation on the ﬁbril surface which is a crucial step
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in the nucleation pathway. We also separately measure the cluster distribution of
monomeric proteins and ﬁnd that inhibitors indeed promote the formation of larger
oligomers. Next, in section 3.2.3 we ﬁnd the average oligomer size on the ﬁbril to
be a unique determinant of the nucleation rate, both in inhibitor's presence and
its absence on the ﬁbril surface. In section 3.2.4 we successfully develop a theory
that explains the relationship between average oligomer size and the nucleation rate
by using and reinterpreting concepts from classical nucleation theory. Finally, we
develop and employ a theoretical lattice model in section 3.3 that takes into account
interactions between particles on the ﬁbril surface and is used to successfully ﬁt
the measured binding isotherms (section 3.3.1), and is able to capture and better
explain the crowding eﬀect using the concept of surface pressure (section 3.3.2).
Lastly, having developed a correspondence between simulation data and the lattice
model, we can investigate the inhibitor design that is most eﬀective at thwarting
self-replication of protein ﬁbrils (section 3.3.3).
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2 Methods
To investigate the inhibition mechanism of surface-catalysed nucleation we employ
a course-grained computational model developed by dr. ari¢ et al. which has been
used to characterise both the spontaneous nucleation mechanism [23, 25], and the
self-replication mechanism [24] of the amyloid aggregation reaction. We then extend
this model by introducing inhibitory particles that can slow down the self-replication
process by attaching to the ﬁbril surface.
Two simulation techniques are widely used in the molecular realm: molecular
dynamics and the Monte Carlo method. Molecular dynamics is used to study clas-
sical many-body systems by integrating equations of motion that are governed by
forces between particles. It probes the time-evolution of the system and can be used
to calculate thermal averages as well as transport properties [31]. Monte Carlo, on
the other hand, is a stochastic integration technique used to calculate thermody-
namic averages by sampling the phase space with discrete random moves. Mostly,
all other things being equal, molecular dynamics would be the simulation method
of choice. But when we are dealing with discrete degrees of freedom such as Ising
spins where we are not interested in the internal dynamics of the transition from
one state to another the use of Monte Carlo is necessary. Our course-grained model
involves conformational changes between discrete protein states which makes the
Monte Carlo method more suited for the task.
2.1 Course-grained model
Our computational model is a course-grained Monte Carlo simulation written in
the C programming language. This model has initially been used to capture the
creation of amorphous oligomers, spontaneous nucleation of ﬁbrils, and elongation
of ﬁbrils [23,26,27], and has been further modiﬁed to capture nucleation catalysed
by the ﬁbril surface [24]. The self-assembly into various morphologies proceeds by
action of non-speciﬁc anisotropic interactions between various monomeric species.
The justiﬁcation for using such a simpliﬁed model comes from experimental evidence
that the mode of attraction between unfolded proteins seems to be largely indiﬀerent
to the change of amino acid structure of aggregation prone proteins as long as the
changed residue has similar properties in terms of hydrophobicity etc. [32, 33]. The
main advantage of such a minimal model is that, being suﬃciently cheap in terms
of computational time, we can explore a wide range of protein concentrations [30].
In its present state the computational model involves a ﬁbril at the center of the
simulation box and a solution of monomeric proteins. These monomers are modelled
as directional hard spherocylinders with an attractive patch that drives assembly
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Figure 1. Coarse-grained computer model for amyloid aggregation. Monomers can
primarily exist in two states: a soluble state that forms oligomers and a β-sheet
state that make up ﬁbrils. When bound to the ﬁbril surface, soluble monomers can
also convert into an intermediate state which forms more tightly bound oligomers
which have a tendency to detach from the ﬁbril surface. Primary nucleation, at
physiologically relevant protein concentrations, proceeds through soluble monomer
oligomerisation and subsequent conversion to a β-nucleus that continues to grow
in solution by elongation. Secondary nucleation is an auto-catalytic process and
proceeds by protein adsorption and oligomerisation on the surface of an existing
mature ﬁbril, conversion into an intermediate oligomer, oligomer detachment, and
ﬁnally conversion into a β-nucleus in a fashion similar to primary nucleation.
(see Fig. 1). Additionally, monomers can take three diﬀerent conformational states:
a soluble `s'-state can form micellar-like oligomers and can bind to the ﬁbril surface,
an intermediate `i'-state is a preﬁbrilar state that can form more strongly bound
oligomers, binds only very weakly to the surface, and has a higher internal free
energy, and a β-sheet rich state which has a very high internal free energy and is
able to form ﬁbrils. Monomers in this β-state have a very strong mutual side-patch
interaction as evidenced by the immense structural integrity of ﬁbril aggregates [34].
Monomeric particles are allowed to swap between these conformations but the con-
version from the lower free energy `s'-state to the higher free energy intermediate
and β-states is thermodynamically unfavourable as well as kinetically slow. There-
fore, these conversions to β-state happen only in large monomer oligomers where
per-particle energy becomes low enough to overcome the entropic barrier associated
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with protein refolding to a more β-sheet rich state. When two β-state particles
form together, we call that a β-nucleus which can only irreversibly grow further by
elongation.
Nucleation can happen by way of primary or secondary nucleation. Primary
nucleation involves a random density ﬂuctuation where soluble monomers form an
energetically favourable but high-entropy oligomer. If this oligomer is suﬃciently
long-lived it can facilitate nucleation by providing an environment in which a con-
version to β-state is energetically favourable. Secondary nucleation involves the
concomitant adsorption of many soluble monomers to some binding site to make
a ﬁbril-bound surface-oligomer. Again, if suﬃciently long-lived, this oligomer can
convert into an intermediate oligomer that has negligible surface aﬃnity but is very
tightly bound. This `i'-oligomer can then detach from the ﬁbril surface and further
grow in solution and/or convert to a β-nucleus in a manner similar to primary nucle-
ation except that the intermediate oligomer is more thermodynamically stable than
its soluble oligomer counterpart. Both nucleation processes are therefore multi-step
because they involve at least both oligomerisation and conversion where monomers
attach/detach or convert one by one.
In this work, we focus on the surface-mediated secondary nucleation because this
process is the source of the majority of toxic oligomers that accompany amyloid self-
replication. As remarked previously, a way to slow down or extinguish the secondary
nucleation process is by covering the ﬁbril surface with inhibitory particles that can
attach to catalytic binding sites and prevent soluble proteins from approaching the
surface. We implement this kind of inhibition in our simulations by introducing a
new particle, called inhibitor. It is modelled as the same spherocylindrical shape
as a monomer and also has an attractive patch at one end with which it can bind
to the ﬁbril surface or possibly to other soluble monomers and inhibitors. This has
been done in order to preserve simplicity in measuring and comparing monomer and
inhibitor coverages which led to simpler analysis of the inhibition eﬀect.
2.1.1 Interactions in the model
In our model, each particle is represented by a spherocylinder with a length to width
ratio of L/σ = 3 which mimics the elementary β-sheet unit in Aβ peptides with
dimensions 2 nm × 6 nm. The unit σ = 2 nm deﬁnes the natural distance measure
in our model against which every other distance is compared. A hard core repulsion
between all particles forbids any distance between any two points on spherocylinder
centerlines to be smaller than σ.
The attractive potential Vss between two monomers in the soluble `s'-state is
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Figure 2. Inhibition of self-replication. Inhibitory particles, depicted in left ﬁgure as
turquoise spherocylinders, can bind to the ﬁbril surface. Inhibitors compete for the
surface binding sites with soluble proteins and therefore slow the rate of secondary
nucleation. The right ﬁgure shows a transmission electron microscopy image of Bri-
chos chaperones functionalised by nanogold-conjugated antibodies clearly showing
binding of the chaperone to Aβ42 ﬁbrils (from ref. [13]).
implemented as:
Vss(r) =
−ss
(σ
r
)6
if r ≤ rcut
0 if r > rcut,
(1)
where r is the distance between the centers of the attractive tips located at the
spherocylinder's ends, rcut = 1.3σ is the cutoﬀ distance, and ss is the maximal
interaction energy between two solubles. An attractive patch is added to only one
of the two spherocylinder poles to ensure formation of ﬁnite micellar-like oligomers
where the tips of soluble monomers are all in contact at the oligomer center (see Fig.
1). The tip-to-tip interaction between other two monomeric particles is implemented
in the same way (Eq. (1)) but with diﬀerent interaction strengths. So we have
ss → ii and ss → si for the interactions between two intermediate monomers and
the interaction between a `s'-state monomer and an `i'-state monomer, respectively,
and possibly ss → ii and ss → sI for the interaction between two inhibitors and
between a soluble monomer and an inhibitor, respectively.
The attractive side-patch of the β-state monomer is Lb = 0.7L long and spans an
angle of 180◦. If patches of two β-state monomers face each other their interaction
Vββ is:
Vββ(r) =
−ββcos
2(φ)− ββ
(σ
r
)
if d ≤ rcut
0 if d > rcut,
(2)
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where 2ββ is the maximal interaction strength between two β-particles, φ is the
angle between the long axes of the particles, d is the shortest distance between the
axes of the patches, and r is the distance between the centers of the patches. The
ﬁrst term ensures that proteins in the β-form pack parallel to each other, mimicking
the hydrogen-bond interactions between β-sheets, while the second term promotes
compactness of the ﬁbrils [3436]. This is also the interaction that holds together the
mature ﬁbril at the centre of our simulation box. To make ﬁbrils thermodynamically
stable, ββ has to be by far the strongest of all the interactions in the system.
The cross-interaction Vsβ between the soluble and the β-sheet conﬁguration is
implemented simply as a potential well:
Vsβ(d) =
−sβ if d < rcut0 if d > rcut, (3)
where d is the shortest distance between the centre of the attractive tip and the axis
of the β-patch, and sβ is the interaction strength. The soluble tip has to face the
180◦ opening of the β-particle side patch. The i-β interaction is described in the
same way, with sβ → iβ. The interactions described above (Eqs. (1),(2),(3)) are
all required to have spontaneous nucleation at physiological conditions.
For secondary nucleation and its inhibition we additionally need binding to the
ﬁbril surface. Adsorption of the soluble protein onto the preformed ﬁbril is given
by:
Vsf (d) =
−sf
(σ
d
)6
if r ≤ rcut
0 if r > rcut
(4)
where d is the shortest distance between the centre of the attractive tip on the soluble
protein and the body of the ﬁbril particle which again extends Lf = 0.7L in length.
Intermediate `i' protein and inhibitor adsorptions onto the ﬁbril are described in
the same way (Eq. (4)), with sf → if , and sf → If , respectively. We note here
that the ﬁbril surface is not uniform as it is made of spherocylindrical monomeric
particles (see Figs. 1 and 2).
2.1.2 Choice of interaction parameters
As this model contains many diﬀerent interactions and particle species it can ex-
hibit many diﬀerent phenomenologies depending on interaction parameters [26]. We
choose parameter values that make surface assisted secondary nucleation possible in
reasonable computer time and keeps the necessary oligomerisation on the ﬁbril and
subsequent oligomer detachment.
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Throughout this work we set the internal free energy of the β-state to 20 kT, the
internal free energy of the intermediate state to 10 kT, and of the soluble state to
zero. The free energy penalty of conversion from a soluble to β-particle is therefore
∆µs→β = 20 kT while the conversion penalties to and from the intermediate state
are ∆µs→i = ∆µi→β = 10 kT. These numbers follow the fact that aggregation-prone
peptides such as Aβ are typically not found in the β-sheet conﬁguration in solution
[37,38].
We choose a relatively low value of `s'-state binding interaction ss = 4 kT even
though the nucleation rate is faster at larger ss where oligomers would be larger and
more long-lived. This was done in order to hinder spontaneous nucleation in solution
whilst still retaining high rates of surface-catalysed nucleation so we do not need to
track both phenomena at the same time. As the `i'-state represents the conformation
with more β-sheet content than the soluble state, we set its interaction strength at
ii = 16 kT. This high value promotes the conversion of a soluble oligomer to an
intermediate oligomer as well as ensures the stability of the detaching `i'-oligomer.
The strength of the interaction between monomers in `i'-state and `s'-state is set to
si = 8 kT which is somewhere in between ss and ii.
The interaction between two β-particles is the strongest by far: ββ = 60 kT.
This high number ensures that the β-nucleus is well deﬁned as a thermodynamically
stable β-dimer, leaving no ambiguity in the measurements of nucleation rate. The
cross-interaction strengths between the soluble or intermediate and the β-state are
sβ = ss + 1 kT and iβ = ii + 1 kT. This means nucleation can happen only in
large oligomers because the free energy penalty of converting one particle to β-state
is oﬀset by many new hydrophobic contributions. For example, in a detached `i'-
oligomer that contains eight `i'-state monomers the free energy change of converting
one monomer to β-state is approximately ∆F8i→7i1β ≈ ∆µi→β − 7(iβ − ii) = 3 kT.
So such a conversion, if attempted, has about e−3 ≈ 5% chance of succeeding.
The interaction strength sf that promotes adsorption to the ﬁbril surface has
also been carefully chosen. If this value is too low (4 kT) there is negligible adsorp-
tion to the ﬁbril and no surface-catalysis. But if too high (say 10 kT) there is no
detachment of oligomer from the surface and therefore no geometrical rearrangement
that allows for conversion to β-state. At certain conditions [24], the maximum rate
of nucleation is achieved at maxsf = 8 kT. We opt for the lower value sf = 6 kT in
order to avoid possible non-monotonic behaviour of nucleation rate when we change
parameters such as soluble chemical potential and inhibitor properties. The inter-
action between `i'-state monomers and ﬁbril particles is set to if = 1 kT. This
low value promotes the detachment of an `i'-oligomer from the ﬁbril while hinder-
ing the ﬁrst conversion of a monomer from soluble to intermediate state. To again
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Figure 3. Interparticle interaction strengths. There are in total eight non-zero
attractive interactions in the non-inhibited computer model: six between various
monomer states (ss, ii, ββ, si, sβ, and iβ) where `s' stands for soluble, `i' for in-
termediate, and `β' for β-state, and two between soluble and intermediate monomer
states (sf and if ). The parameter values were chosen such that secondary nucle-
ation on the ﬁbril surface is favoured to spontaneous nucleation in solution and such
that only large surface-oligomers have a chance to detach and nucleate.
make a quick back of the envelope calculation, the free energy change to convert
one soluble state particle to intermediate state in a surface oligomer of six solubles
is ∆F6s→5s1i ≈ ∆µs→i + 5(ss − si) + 2(sf − if ) = 0 kT. So, if attempted, there is
a fair chance a large oligomer will be able to nucleate.
Finally, we vary the inhibitor binding strength between If = 6−8 kT, mimicking
the experimental situation where inhibitors have a larger aﬃnity for the ﬁbril sur-
face than unfolded proteins [13]. We nominally set both the inter-inhibitor binding
as well as the interaction strength between inhibitors and monomers to zero, that
is II = sI = 0. Later, when investigating optimal inhibitor design, we also try
non-zero values of these parameters (section 3.3.3) but the majority of this work is
done with no cooperative inhibitor binding and without mixed oligomers.
2.1.3 MC simulation
Simulations were performed in a periodic cubic box in a semi-grand canonical en-
semble where we kept the volume of the box V , the temperature T , the chemical
potential of monomers µm, and total number of inhibitors NI constant. Such a
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scheme was chosen to avoid the depletion of monomers and inhibitors from solu-
tion due to adsorption onto the ﬁbril surface and to have good control over the
number of particles simulated. All simulations start with a simulation box of size
150σ × 150σ × 150σ, a preformed ﬁbril at the center of the box and 600 randomly
distributed soluble monomers. The ﬁbril contains 92 tightly bound side-patched
particles and is capped at both ends (unable to grow by elongation) as we want to
keep the amount of binding sites constant. We also randomly distribute a certain
amount of inhibitors NI = χ·600, depending on the parameter χ that we input in the
program. We then scale the simulation box, making it larger or smaller, to match
the speciﬁed soluble chemical potential µm by making grand-canonical exchange
moves that add or removes soluble monomers from anywhere in the simulation box,
excluding the D = 12σ wide exclusion zone around the preformed ﬁbril. During
scaling, we also reinsert inhibitors that ﬁnd themselves outside the simulation box
by placing them randomly inside the box. We make those replacements during scal-
ing and not after because inhibitors in solution interact with monomers via volume
exclusion, thus inﬂuencing µm. We settled for 20 rescaling moves and 60 exchange
grand-canonical moves that removed or added soluble monomers according to µm
and box volume.
We note here that we could take a more elegant, fully grand-canonical route
in preparing the simulation by ﬁrst specifying a ﬁxed box size and then distribute
monomers and inhibitors inside the box according to their chemical potentials. This
way we would have direct control on the real chemical potentials of both species
separately. Unfortunately, the eﬀect of this route is that we would, depending on
the values of chemical potentials, sometimes simulate 2000+ particles which would
be very expensive in terms of computational time or simulate only 100− particles
which could potentially introduce ﬁnite-size eﬀects.
After the simulation is initialised we run the `equilibration simulation' for an
indeﬁnite number of Monte Carlo steps. In such a simulation we let the soluble
monomers and inhibitors explore the conﬁguration space until the system reaches
equilibrium - some solubles and inhibitors adsorb to the ﬁbril, some form oligomers,
most remain in solution. At this point we do not allow for possible conversions
between monomer states because we ﬁrst want equilibrium conditions on the ﬁbril
surface where the surface and solution chemical potentials of a given species are
equated. We ﬁnd this dynamic equilibrium state by looking at the graphs of the
number of soluble monomers and inhibitors adsorbed to the ﬁbril against simulation
`time' (see Fig. 4). When the adsorbed particle numbers are observed to ﬂuctuate
around a mean, the system is on average in its lowest free energy state.
After we have reached equilibrium we manually stop the simulation and input
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Figure 4. Reaching dynamic equilibrium state. a) the number of soluble monomers
in the solution (red) is kept constant on average by grand-canonical exchange moves.
b) Equilibration of chemical potentials between solution and ﬁbril surface is achieved
when both the number of ﬁbril-bound monomers (green) and inhibitors (blue) start
ﬂuctuating around a mean.
its last conﬁguration into a new `rate simulation'. This simulation ﬁrst runs for a
further 500.000 Monte Carlo steps so we can measure and average the equilibrium
properties such as monomer and inhibitor coverages of the ﬁbril surface, monomer
oligomer distribution on the surface, monomer and inhibitor number densities in
solution, average per-particle binding energies of both species on the ﬁbril, and
monomer cooperative binding energies in oligomers.
After the measurement phase we switch on the Monte Carlo routines that govern
conversion between diﬀerent monomer states. During conversion, the position of the
particle and the orientation of the spherocylinder's long axis are conserved. If the
peptide conversion is between an `s' or `i'-state to a β-state, we also randomly assign
the orientation of the β-sheet side-patch. The probability of attempting a conversion
move was set to pswap = 1/5000, which mimics the slow conversion of the soluble
unfolded protein into a β-sheet prone conﬁguration.
Overall, each Monte Carlo step involves N translational and orientational moves,
where N is the total number of particles in the system (inhibitors, monomers in
various states, and ﬁbril particles). Additionally, for β-state monomers and ﬁbril
particles there is an additional random rotation around the spherocylinder's long
axis. The chance of these translational and orientational moves being accepted is
governed by the Metropolis algorithm. Also, with a chance of pexchange = 1/30.000 in
each step, we perform Ns grand-canonical exchange moves, where Ns is the number
of soluble monomers outside the exclusion zone. Finally, each step, all monomers
are given a chance to change their conformation between the `s', `i' or β-state. The
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simulation terminates when we observe two mutually bound β-particles that deﬁne
the β-nucleus.
Depending on the values of monomer and inhibitor chemical potentials and in-
hibitor binding aﬃnity, the initialisation phase takes up to two hours, equilibration
phase from one to four days, and nucleation phase from just hours to inﬁnite time
but we ran the rate simulations for at most 14 days. The highly stochastic nature
of the nucleation rate measurements forces us to make many repetitions for a given
set of parameters. Therefore all parameter sweeps were performed on the compu-
tational cluster `Dexter' that contains 480 computing nodes and is located at the
Department of Chemistry, University of Cambridge.
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3 Results
The results section is structured as follows: ﬁrst we perform simulations at condi-
tions that have been used in a previous study [24] where no inhibitors are present
and conﬁrm that our code is working properly in the limit of no inhibitor particles.
We discuss the relevant measured variables such as monomer coverage, oligomer
distribution on the ﬁbril, and nucleation rates. Then we introduce inhibitors in our
simulations and observe how they inﬂuence monomer coverage on the ﬁbril. We
ﬁnd that binding isotherms cannot globally be ﬁtted with the Langmuir competi-
tive binding model because of volume-exclusion interactions between monomers and
inhibitors on the ﬁbril. Looking at the rate of nucleation under the inﬂuence of
inhibitory particles we discover that the reported nucleation mechanism where the
rate is simply dependent on monomer coverage [24] fails when inhibitors are present
on the ﬁbril due to macromolecular crowding. We therefore look for a more gen-
eral metric that is able to uniquely describe the rate of secondary nucleation and
ﬁnding it to be the average oligomer size on the ﬁbril. Having found this unique
determinant of the rate we build a theory that uses concepts from the classical nucle-
ation theory. Using our theory, we successfully ﬁt our simulation data. Finally, we
develop a statistical-mechanical lattice model that is able to explain the non-ideal
binding isotherms, provide some insight into macromolecular crowding, and make
useful predictions for eﬀective inhibitor design.
3.1 Absence of inhibitor
Due to implementing a new particle into the existing simulation scheme for studying
secondary nucleation, we made quite a few changes to the program written in C.
Therefore, we needed to make sure the underlying code for the secondary nucleation
remained intact. We did that by reproducing some of the results published in
[24]. We performed a parameter sweep across a broad range of monomer chemical
potentials µm ∈ [0.71, 7.04] kT in the absence of inhibitor particles and at exactly
the same binding strength parameter values that were used in the previous study
(see Fig. 3).
3.1.1 Monomer coverage and the rate
In our simulations, the ﬁbril surface is not uniform but is made up of 92 ﬁbril particles
with a Lennard-Jones type interaction (Eq. (4)). Binding sites are therefore not very
well deﬁned; in simulations, an adsorbed particle would mostly dock with its tip into
a pocket between two ﬁbril particles (see Fig. 3, left) as this is the place with the
lowest potential energy. Alternatively, it could sit on top of one ﬁbril particle while
15
still interacting with the neighbouring two ﬁbril particles. Additionally, depending
on the strength of interaction between two adsorbed soluble monomers (ss), the
adsorbed particles may stack upon one another. This can pose a diﬃculty in deﬁning
the monomer coverage but because most of our simulations are done at a constant
temperature (T ), and constant binding strengths ss and sf , we will simply deﬁne
monomer coverage (θm) as:
θm =
Nmon(µm)
Nmon(µm →∞)
∣∣∣∣
T,ss,sf
, (5)
where Nmon is the number of soluble monomers adsorbed to the ﬁbril. We can eval-
uate the maximum value of adsorbed monomers by ﬁtting the data to the Langmuir
isotherm:
θm =
cmon/Km
1 + cmon/Km
, (6)
where cmon is the measured concentration and Km is the monomer dissociation
constant. We measure the concentration by simply counting the number of soluble
monomers in the bulk volume (outside the ﬁbril exclusion zone), dividing by that
same volume, and averaging over multiple equilibrium conﬁgurations. By comparing
the two coverage equations (Eq. (5), (6)) and ﬁtting to measured data (Fig. 5a), we
getNmon(µm →∞) = 156±2, which is more than twice the number of ﬁbril particles,
and Km = (4.42± 0.07) · 10−3 σ−3. To convert from the simulation number density
units into SI units, we need to multiply by 0.208mol/L to getKm = (0.92±0.02)mM.
We note however, that the exact numbers are not important to our discussion as
they crucially depend on our choice of interaction parameters. We will therefore
always use simulation units throughout this work and will simply use a shorthand
σ−3 ≡M .
The rate of secondary nucleation is calculated from the average lag time for
nucleation < tlag > which is deﬁned as the average number of Monte Carlo steps
needed to obtain a β-nucleus. Regardless of the value of the monomer chemical
potential, we average over 9 successful realisations of the stochastic process (black
circles in Fig. 5) with diﬀerent random seeds but starting from the same equilibrium
conﬁguration. The lag time is expressed in the units of 105 MC steps. Using the
equivalence between the average ﬁrst exit time < tlag > across the free energy barrier
and the inverse of the associated Kramers rate (r), we have:
r =
1
< tlag >
. (7)
Plotting the logarithm of the secondary rate against monomer concentration in
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Figure 5. Monomer adsorption and nucleation rate in absence of inhibitor. The left
graph (a) shows the variation of the number of monomers adsorbed (Nmon) with
respect to monomer concentration (cmon) in log scale. It shows a linear regime at
low concentrations and a saturation regime at higher concentrations. The graph is
ﬁtted with a Langmuir isotherm (6) yielding the maximum number of monomers
adsorbed 156 and a dissociation constant Km = 4.42mM. The ﬁt is not perfect
because of volume exclusion and cooperative binding interactions on the ﬁbril and
mostly serves as a guide to demonstrate the saturation eﬀect. On the right (b), we
plot the rate of secondary nucleation (r) with respect to monomer concentration
(cmon). This graph also demonstrates a linear and a saturation regime indicating
that the rate is crucially dependent on monomer coverage. Each black circle stands
for a particular realisation of the stochastic process while cyan circles with error
bars represent the ensemble average over nine realisations with the same parameter
set but diﬀerent initial conditions.
Fig. (5b), we immediately see that the rate exhibits saturation at higher concentra-
tions. The scaling exponent γs =
d ln(r)
d ln(cmon)
is highly dependent on monomer concen-
tration, ranging from about 3.0 at low concentrations to 0.5 at high concentrations.
This indicates that the dominant aggregation mechanism changes with concentra-
tion as was experimentally found for Aβ40 amyloid aggregation [9]. Comparing the
two graphs in Figure 5, we can see that the change in the scaling factor γs follows the
trend in the change of ﬁbril coverage. The change of γs, therefore, seems to be caused
by the surface saturation. This is a plausible conclusion since secondary nucleation
ought to be a surface-catalysed phenomena so monomer coverage, not monomer
concentration, directly inﬂuences the rate of secondary nucleation. This claim has
been further conﬁrmed by varying the protein surface aﬃnity at constant monomer
concentration, both in simulations (changing sf ) and in experiments (changing the
salinity to inﬂuence ionic screening) [24].
Yet another striking conﬁrmation that monomer coverage determines the rate
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of secondary nucleation comes from studying the variation of rate and monomer
coverage with temperature [11, 39, 40]. In these simulations, we keep the monomer
chemical potential constant and only vary the temperature which inﬂuences both
the adsorption to the ﬁbril and the success of conversions. These simulations were
performed to study the multi-step nucleation pathways of primary and secondary
nucleation in relation to Kramers rate theory. The results have recently been pub-
lished in [41] but will not be a topic of this thesis due to lack of space. In Fig.
6a we overlay three diﬀerent datasets on a parametric plot of the rate of secondary
nucleation against monomer coverage. One dataset (blue) is the same as in Fig.
5 where we vary the monomer chemical potential at constant temperature T = 1,
while the other two (green, red) datasets are obtained by varying the temperature
at constant chemical potentials µm(green) = 4 kT and µm(red) = 3 kT, correspond-
ing to monomer concentrations cmon(green) = 2.0mM and cmon(red) = 0.72mM,
respectively (see Fig. 6b).
Figure 6. Coverage of the ﬁbril surface determines the nucleation rate. a) para-
metric plot of secondary rate (r) against monomer coverage (θm) for three diﬀerent
parameter sweeps. Blue points are obtained by varying monomer chemical potential
at a constant temperature, while green and red are obtained by varying the temper-
ature at constant chemical potential. All three datasets collapse on the same curve
indicating that monomer coverage solely determines the rate of self-replication. b)
The variation of the rate with inverse temperature for two chemical potentials. The
rate increases with lowering the temperature as more solubles adsorb to the surface.
We can see that all three datasets collapse on the same line at low to interme-
diate monomer coverages and diﬀer only slightly in the saturation regime. We can
therefore write with some conﬁdence the relation between monomer coverage and
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secondary rate as:
r ∼ θN∗m , (8)
whereN∗ is the surface reaction order for the self-replication reaction and is expected
to be related to the size of a nucleating oligomer at the top of the highest relative
free energy barrier.
3.1.2 Nucleation mechanism
Having demonstrated that the rate of nucleation is entirely dependent on ﬁbril sur-
face coverage by soluble monomers, we now turn to explain the molecular steps
of the underlying nucleation mechanism. As mentioned earlier, nucleation in our
model proceeds through four visually diﬀerent and easily deﬁned molecular steps
(Fig. 1d): oligomerisation on the ﬁbril surface where many solubles form a micelle-
like surface-oligomer by adsorbing in the vicinity of each other, conversion of that
surface oligomer into an `i'-oligomer that contains only monomers in the interme-
diate state, detachment of the `i'-oligomer and ﬁnally conversion to a β-nucleus.
Each of these steps contain many smaller steps where monomers attach or convert
one-by-one. Needless to say, the free energy landscape for such a nucleation path
is very complex. Additionally, nucleation can take many diﬀerent paths along the
multi-dimensional free energy landscape, a problem we will tackle in section 3.2.4.
Nevertheless, we can still determine which of the major steps inﬂuences the rate
of nucleation most. We do that by measuring the scaling exponents for diﬀerent
steps in the nucleation reaction for diﬀerent values of the conversion attempt prob-
ability (pswap). The result of increasing this swap probability is, in eﬀect, that all
conversion free energy barriers are lowered by a constant amount while adsorption
and oligomerisation processes remain unaﬀected. We measured the time lags for
several states along the nucleation pathway: the simulation time it takes to observe
the ﬁrst monomer conversion to the intermediate state, the time it takes to observe
two mutually bound `i'-state monomers, three mutually bound `i'-state monomers,
the time of ﬁrst conversion to β-state, and the time to form a β-nucleus or nucleation
time.
By analysing the data and observing the simulation trajectories we ﬁnd that nei-
ther the ﬁrst nor the second conversion of adsorbed monomer to intermediate state
necessitates a nucleation event. Only when at least three monomers are mutually
bound in their intermediate state do we always achieve nucleation. This indicates
that a surface oligomer with three `i'-state monomers (`i3'-oligomer) is already a
stable thermodynamic species. The subsequent conversion to a fully intermediate-
state oligomer and detachment are even more thermodynamically favourable and
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will necessarily happen.
Figure 7. Identifying the rate-limiting step by varying the conversion attempt prob-
ability pswap. We plot the rate of nucleation (a), rate of formation of a surface-bound
`i3'-oligomer (b), and the rate of conversion between a detached `i'-oligomer and an
oligomer that has one monomer transformed to β-state (c). By comparing the scal-
ing exponents (γs, γinter, and γβ1) we can infer that the rate of nucleation is mostly
dominated by the formation of an `i3'-oligomer, making it the rate determining step.
In (d) we plot the nucleating oligomer size when in `i3'-oligomer form and by how
much it grows in solution after it detaches. All data is measured at the same pa-
rameter values as in Fig. (5) while each point on the graph is the result of averaging
over 5 simulation runs.
The next slow step is the conversion of one `i'-state monomer to a β-sheet particle
inside a detached oligomer. This conversion is also unfavourable as already sketched
in section 2.1.2. To facilitate easier conversion to β-state, the oligomer grows further
in solution by conscripting nearby monomers. In principle, each monomer addition
is favourable until we reach a geometrical constraint because only a ﬁnite number of
monomers (about 12) can take full advantage of micellar interactions. In an enlarged
oligomer, conversion to β-state is more available and such a state more long-lived;
enough, in fact, to facilitate another conversion `i'→ β. This ﬁnal conversion to a
β-nucleus is very favourable because of the very strong β-β hydrophobic interaction.
All subsequent conversions and monomer additions go thermodynamically downhill
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from there in a type of irreversible polymerisation reaction.
In short, we have identiﬁed three main checkpoints on the nucleation pathway:
the surface oligomer that contains three `i'-state particles, the detached oligomer
that contains one β-sheet particle and the ﬁnal β-nucleus state. We plot the inverse
of the average simulation time lapsed between these checkpoints in Fig. 7. It shows
the rate of nucleation (a), the rate of creation of an `i3'-oligomer (b), and the rate of
transformation from that oligomer to a detached oligomer with one β-sheet particle.
By comparing these graphs we immediately see how the rate of nucleation follows
very closely the rate of `i3'-oligomer formation; especially we can appreciate that the
saturation of `i3'-oligomer formation rate at high monomer concentrations causes
the saturation eﬀect in the nucleation rate. But depending on parameter values, the
conversion of one particle to β-state also plays a major role. This is especially true for
the dataset with pswap = 1/50 where the rate of conversion to β-state is slower than
the rate of `i3'-oligomer formation at low monomer concentration. In this regime,
the scaling of nucleation rate with concentration is governed by β-conversion scaling
as can be seen by comparing scaling exponents (γs and γβ1 in Fig. 7). Another
exception is that at very high surface saturation the free energy barrier for making
an intermediate oligomer is nigh non-existent so again the ﬁrst conversion to β-state
becomes the rate limiting step.
To conclude this section, we have successfully replicated the monomer coverage
and nucleation rate data from previous work [24] where the authors have found, both
in experiments and in silico, that the rate of self-replication is governed by monomer
coverage of the ﬁbril surface. We have further provided evidence for this assertion by
performing simulations where we varied temperature instead of monomer chemical
potential. Making a parametric plot of nucleation rate against monomer coverage,
all data collapsed on the same line. Finally, we have identiﬁed and characterised
the major molecular steps along the nucleation pathway. We have found that the
formation of a partially converted surface-oligomer is the most important and could
be considered a rate-limiting step in our simulations while the conversion from the
detached `i'-oligomer to β-nucleus also requires mounting a free energy barrier and
can also be rate-limiting under certain conditions. Incidentally, it has been only
very recently demonstrated [42] through a combination of novel experiments and
chemical kinetics theory that this latter step is indeed very rare and that only a
small number of detached oligomers ultimately form a ﬁbril nucleus. This means
that many toxic oligomers are recycled before ultimately converting to a growth
competent ﬁbril nucleus. These simulations aided in providing a justiﬁcation that
such a mechanism is indeed possible.
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3.2 Inﬂuence of inhibitor
We now turn to investigate the inﬂuence of surface-bound inhibitory particles on
the nucleation pathway. In this section, we report the results of simulations that we
performed at various inhibitory conditions: we explored how binding of monomer
and the rate of nucleation changes if we add inhibitors at a constant monomer
chemical potential or if we keep a constant ratio of the monomer and inhibitor
number densities in solution. Additionally, we explored the inﬂuence of the strength
of inhibitor-ﬁbril binding aﬃnity on the nucleation pathway. The compiled data is
the result of over a thousand well-equilibrated simulations that together took well
over a 100.000 hours of computer time. We will analyse and explain the results in
separate subsections.
We start by simulating a ﬁbril in solution of monomers and inhibitors that both
have the same chemical potential (cmon = cI). An inhibitor also binds to the ﬁbril
surface with exactly the same binding strength as soluble monomer (If = 6 kT)
but has no cooperative binding interaction (II = 0). We performed a sweep across
several chemical potentials of both species and obtain a green curve in Fig. (8a,c)
where we plot it alongside the blue curve which is obtained by simulating without
inhibitors (same data as in section 3.1). We can immediately see that for all monomer
concentrations the green curve lies below the blue curve. This indicates that the
presence of inhibitors always reduces monomer coverage and the rate of nucleation.
Next, we performed simulations by keeping the monomer chemical potential
constant at (µm = 4.08 or ln(cmon/M) = −6.28) while changing the concentra-
tion of inhibitors in solution from 0 to two times the concentration of monomers
(cI/cmon = 2.0). We did that for three diﬀerent inhibitor-ﬁbril interaction strengths:
for sf = 6 kT, represented by red, for sf = 7.2 kT, plotted in violet, and sf = 8 kT,
plotted with the orange colour. Although this diﬀerence in binding strength appears
only minor, it is ampliﬁed by the fact that one inhibitor particle binds to 2− 3 ﬁb-
ril particles at the same time. Looking at Fig. 8b,d, we again see that both the
monomer coverage and the rate of secondary nucleation monotonically drop when
increasing the concentration of inhibitors in solution. There is a small kink in nu-
cleation rate for very low inhibitor concentrations in red data but this is well within
the stochastic error. Inhibitors with higher aﬃnity to the surface better inhibit
self-replication at a given inhibitor concentration than those with lower aﬃnity.
Comparing graphs that show monomer coverage with those that show the rate
of nucleation, we can again appreciate that the rate seems to be determined by the
amount of monomers adsorbed on the surface which has been succinctly expressed
by equation (8). The data suggests that the inhibitory eﬀect of inhibitory particles
simply stems from their ability to occupy some binding sites on the ﬁbril, making
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them inaccessible to monomer particles, and therefore driving down monomer cover-
age and the associated secondary rate. In short, the mechanism of inhibition seems
mainly to be that monomers have to compete with inhibitors for the same binding
sites.
Figure 8. Inhibitors drive down the rate of nucleation. a,b) In the presence of in-
hibitors, monomer coverage (θm) drops for all combinations of inhibitor (cI) and
monomer concentrations (cmon) and all probed inhibitor-ﬁbril binding strengths
(sf ). c,d) Following the trend of monomer coverage, the rate of secondary nu-
cleation (r) also signiﬁcantly decreases by action of inhibitors.
3.2.1 Binding isotherms
Competition between two or more species for the same binding sites is a well known
and studied phenomena. We employ here an ideal competitive-Langmuir model to
see if it can explain the binding behaviour of monomers and inhibitors at various
simulated conditions. The Langmuir adsorption theory describes binding to a lattice
with M binding sites, all of which are equivalent, distinguishable, independent, and
also do not facilitate interactions between adsorbed particles [43]. If these conditions
are met, then, regardless of particular arrangement of lattice sites, the competitive
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binding between monomers and inhibitors can be described by the following binding
isotherms:
θm =
cmon/Km
1 + cmon/Km + cI/KI
, (9)
and
θI =
cI/KI
1 + cmon/Km + cI/KI
, (10)
where Km and KI are monomer and inhibitor dissociation constants and θI is in-
hibitor coverage of the lattice sites. We have already used a one-species Langmuir
curve (Eq. (6)) to successfully ﬁt the monomer adsorption data in Fig. (5). So we
have already obtained the value of Km in that ﬁt as well as the maximal possible
number of monomers adsorbed (Nmon(µm → ∞)). We normalise all our measured
adsorption data with that maximal number, including the inhibitor adsorption data
to get the inhibitor coverage as:
θI =
NI
Nmon(µm →∞) , (11)
where NI is the measured number of inhibitors adsorbed on the ﬁbril surface. We
plot the normalised monomer and inhibitor coverages in Fig. 9. We make two
Langmuir ﬁts for each dataset: the violet line represents a ﬁt to monomer coverage
(Eq. (9)) with KI the only ﬁtted parameter, and the green line shows a ﬁt to
inhibitor coverage (Eq. (10)) with again KI the only ﬁtted parameter. The black
curve, on the other hand, shows the Langmuir curve for inhibitor coverage (Eq.
(10)) if we use the ﬁtted value KI , obtained when ﬁtting the violet curve.
Going in order, we can see in Fig. 9a that the ﬁt to monomer coverage is quite
good; we get a value of KmonI (If = 6 kT) = (1.3 ± 0.1)mM. Instead, if we try to
ﬁt KI to inhibitor coverage, we get an equally good ﬁt yielding KinhI (If = 6 kT) =
(8.3 ± 0.1)mM. There is a very large discrepancy between these two ﬁts (KmonI
and KinhI ) as can be seen by plugging K
mon
I in the formula for inhibitor coverage
(Eq. (10)); we get a black curve which completely misses all inhibitor coverage data
points. So both coverages can be successfully ﬁtted separately but not at the same
time with only one shared ﬁtted parameter.
Looking next at Fig. 9b, we can see that while monomer coverage ﬁt works ﬁne,
yielding KmonI (If = 7.2 kT) = (0.17 ± 0.01)mM, we can no longer adequately ﬁt
the inhibitor coverage data (the closest ﬁt gives KinhI = (2.0±0.1)mM). Comparing
the ﬁtted KI 's for If = 6 kT and If = 7.2 kT we can appreciate that just a small
increase in binding strength (1.2 kT) makes the dissociation constant fall by an order
of magnitude. Incidentally, we can successfully perform a ﬁt to inhibitor coverage
data if both KI and Km are free parameters. So the shape of the curve is still
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Figure 9. Binding isotherms. Monomer (violet, θm) and inhibitor (green, θI) cover-
ages for four diﬀerent datasets. a,b,c) Keeping the monomer concentration constant,
at ln(cmon/M) = −6.28, we vary the concentration of inhibitors (cI) with binding
strengths If = 6 kT (a), If = 7.2 kT (b), and If = 8 kT (c). In d) we vary both
monomer and inhibitor concentration, keeping the ratio cI/cmon = 1 constant. The
violet, green and black lines represent ﬁts to the competitive-Langmuir isotherms
(Eq. (9) and Eq. (10)).
approximately Langmuir but the dissociation constants eﬀectively change in that
regard.
Next, in Fig. 9c, we see that neither inhibitor nor monomer coverage can be well
ﬁtted with a Langmuir curve. The monomer coverage ﬁt gives KmonI (If = 8 kT) =
(0.035 ± 0.003)mM and the inhibitor ﬁt KinhI = (0.72 ± 0.06)mM. Separate ﬁts
with two loose parameters again work but are very under-determined and therefore
do not hold much meaning. Finally, in Fig. 9d, we can see that for our constant
concentration ratio data, the Langmuir ﬁts fail completely. What is more, the ﬁts
fail even when performed with two free parameters.
We can therefore conclude from Figure 9 that the Langmuir binding isotherms
serve as a good starting point - they describe surface saturation behaviour, compe-
tition between species, and the dependence of KI on If - but are not adequate to
explain the binding behaviour. The most obvious reason would be that our simulated
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particles interact via volume exclusion and in the case of monomers by tip-to-tip
attraction. However, one would expect that at least at very small coverages these
non-ideal eﬀects would be suppressed. But importantly, as signiﬁed by the crimson
coloured points in Fig. 9, the total coverage of the ﬁbril surface is at least 30% for
any simulation. This means that the surface is quite crowded with particles that
possibly interact with each other via volume exclusion and this is more than enough
to introduce non-ideal binding behaviour. We will discuss a model that takes into
account interactions on the ﬁbril in section 3.3.
3.2.2 Macromolecular crowding
In the absence of inhibitors, we ﬁnd that the rate of secondary nucleation is governed
by soluble monomer coverage of the ﬁbril surface (see Fig. 6a and Eq. (8)). However,
with inhibitors present on the surface, we ﬁnd a dramatic discrepancy from the
expected behaviour, as shown in Figure 10a where we join all datasets on the same
graph of rate against monomer coverage. Inhibitors on the ﬁbril indeed decrease
the amount of the ﬁbril surface available for monomer binding, but the rate of self-
replication does not decrease to the extent predicted by Equation (8). At a given
monomer coverage, we ﬁnd self-replication to be faster in the presence of inhibitors.
Looking at data points (red, violet, orange) where we increase inhibitor concen-
tration at constant monomer concentration ln(c0/M) = −6.28mM but for diﬀerent
surface binding aﬃnities, we see that all of these points fall on the same line. This
might suggest that inhibitors on the ﬁbril somehow alter the reaction order N∗ which
is related to the number molecules interacting in the slowest, rate-determining step.
One could for example argue that the surface-bound inhibitors block the formation of
larger oligomers. However, as shown in the inset of Fig. 10b, the nucleating oligomer
properties remain unchanged under the inﬂuence of inhibitors. Also, blocking larger
oligomers would predict better inhibition compared to simple competitive binding,
not worse as seen in Fig. 10a. Additionally, the data where we vary monomer and
inhibitor concentrations simultaneously (green) does not show this apparent change
in reaction order.
Another possibility would be that by occupying some binding sites, inhibitors
eﬀectively increase monomer coverage by reducing the number of available sites as
θm → θmM/(M − NI) = θm/(1 − θI) where M is the number of all ﬁbril binding
sites and NI is the number of adsorbed inhibitors. If we renormalise monomer
coverage in that way, we get the graph in Fig. 10c. We can see that the shift
in monomer coverage is not suﬃcient to explain the discrepancy between inhibited
and non-inhibited data. Nevertheless, the shift is in the right direction. A possible
justiﬁcation for performing such a transformation monomer coverage would be that
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at a given number of monomers adsorbed to the ﬁbril, the presence of inhibitors
redistributes adsorbed monomers in a way that we get higher local coverages at
some parts of the ﬁbril and lower local coverages on other parts of the ﬁbril surface.
This explanation is well supported by the fact that nucleation is a very localised
event and the result of a ﬂuctuation in oligomer size.
Figure 10. Inhibitors inﬂuence the rate of nucleation in a non-trivial way. a) The
relation between monomer coverage (θm) and the rate of nucleation (r) is perturbed
in the presence of inhibitor. b) This perturbation is caused by crowding between
species on the surface. If we take volume-exclusion into account, all data collapses
on the same curve. Inset: the presence of inhibitors does not inﬂuence the subcluster
size of nucleating oligomers (Nsub). c) One possible but unsatisfactory explanation
for branching in a) was that inhibitors redistribute monomers on the surface, re-
sulting in higher local coverages of monomers. d) An example of a misﬁt, using a
smaller value of parameter α.
To investigate how inhibitors inﬂuence the distribution of monomers on the ﬁbril,
we measured the cluster size distribution for various combinations of monomer and
inhibitor chemical potentials. To extract valuable information from these distribu-
tions we compare the normalised distributions n(N) at a given monomer coverage
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but for diﬀerent inhibitor coverages and binding aﬃnities. We plot the distribu-
tion in Fig. 11 where we can clearly see that the distributions are shifted to larger
oligomer sizes in the presence of inhibitors: the blue bar that shows the distribu-
tion in inhibitor absence is higher for sole monomers and lower for larger oligomers
compared to distributions with inhibitor present. Remembering that a formation of
a suﬃciently large oligomer which can facilitate conversion to intermediate state is
a crucial step in nucleation, we can recognise the shift in oligomer size distribution
as the reason for deviating behaviour in Fig. 10a.
This inﬂuence on oligomer formation that is exerted by inhibitors on the ﬁbril
is a clear manifestation of a macromolecular crowding eﬀect. Inhibitors have a non-
negligible volume and due to volume-exclusion repel other proteins on the ﬁbril,
pushing them towards each other. As a result, even though the overall rate of self-
replication drops due to competitive binding, the decrease in nucleation rate is to
a lesser extent than predicted by Eq. (8) which eﬀectively treats monomers and
inhibitors as point-particles.
We phenomenologically capture this crowding eﬀect by stating that inhibitors
eﬀectively decrease the free energy of oligomerisation for oligomers of all sizes by
amount ∆∆Folig. By virtue of being surrounded by voluminous inhibitors, an assem-
bled oligomer has to push against neighbouring inhibitors in order to disintegrate
back into free monomers. By doing so, it has to perform positive work Wolig which
has to be supplied by the free energy diﬀerence between the assembled oligomer state
and a collection of free monomers (or any lower-size oligomer state in between).
We model this work term by making it simply proportional to inhibitor coverage:
Wolig ∼ θI ; more inhibitors on the ﬁbril at given monomer coverage means more
clustering of monomers. We can therefore write the reduction in the free energy of
oligomerisation as:
∆∆Folig = −kTαθI , (12)
where α is an undetermined proportionality factor.
Oligomerisation precedes all nucleation events so all nucleation pathways can
be modelled to be aﬀected in the same way by inhibitors. We can therefore, using
Equation (8), write the rate of nucleation (rI) in the presence of inhibitors and at
speciﬁed monomer coverage as:
rI ∼ θN∗m · e−∆∆Folig(θI)/kT (13)
or, by additionally using the model (12), write the rate law as:
rI ∼
(
θm · eα/N∗θI
)N∗
. (14)
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We recognise the expression θm · eα/N∗θI as eﬀective monomer coverage of the ﬁbril
surface (θeff ) that governs the rate of nucleation both in absence or presence of
inhibitors.
Plotting the rate of nucleation against this eﬀective coverage, we can see that
for α = 2N∗ all data collapses precisely on the same curve (Fig. 10b). Smaller (see
Fig. 10d) or larger value of the ﬁtted parameter α results in a misﬁt so the value
of α has to be precise. This result where all data collapses on the same curve is
remarkable because it seems to hold for all possible combinations of monomer and
inhibitor coverages and surface binding aﬃnities. So we can be quite conﬁdent that
the rate of secondary nucleation is uniquely determined by both θm and θI at a given
set of interaction parameters.
However, without knowing the meaning of the parameter α, this theory of in-
hibitor inﬂuence on the free energy barrier to form an oligomer is just a phenomeno-
logical explanation and its use cannot easily be extrapolated beyond our computer
model. One reasonable explanation would be that in the work term (Eq. (12)),
kT θI could stand for pressure while α could stand for the number of binding sites
released when an oligomer disintegrates against the pressure of inhibitors. The best
ﬁtted value however, implies α ≈ 10, a number that is much greater than most
oligomer sizes in our simulations.
3.2.3 Average oligomer size
There is another metric that is able to uniquely determine the nucleation rate - the
average oligomer size on the ﬁbril surface. We have learned that inhibitors shift
the oligomer distribution towards larger oligomer sizes (Fig. 11b) and we know
that larger oligomers better facilitate conversions of monomers to other states and
eventually nucleation. Remarkably, surface-oligomer sizes follow a simple negative
exponential distribution which means that the information about the whole distri-
bution can be captured by a single number - the average oligomer size (N).
We plot the rate against N in Fig. 11 and ﬁnd that all points follow the same
monotonic curve. This is a much stronger result than the one regarding eﬀective
monomer coverage because it is general for many diﬀerent interactions on the ﬁbril
between monomers and inhibitors. It should hold as long as inter-protein interactions
on the ﬁbril inﬂuence only the oligomerisation part but not the conversion part of the
nucleation process. We conﬁrmed that by looking at the size of nucleating oligomers
and found it unchanged in inhibitor's presence. There was an issue with that claim
at ﬁrst because we were only measuring the size of a β-nucleus which, as discussed
in section 3.1.2, is not the most important step in the nucleation process. But when
taking into account that a nucleating oligomer grows before ﬁnally nucleating, we
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arrived at the correct number for the nucleating oligomer size (Nnucl). Using this
value Nnucl and the average oligomer size, we were able to develop a theory for
determining the rate of self-replication without any undetermined parameters. We
discuss this theory at length in the next section.
Figure 11. Average oligomer size uniquely determines the rate of self-replication.
a) Plotting the rate of nucleation (r) against average oligomer size (N), all data
collapses on the same curve. We can ﬁt a theoretically derived formula where the
average oligomer size and the average nucleating oligomer size (Nnucl) determine the
rate of nucleation. b) The normalised monomer cluster size distribution (n(N)) on
the surface at a given monomer coverage but diﬀerent inhibitor concentrations and
binding aﬃnities. The distribution shifts towards larger oligomers with inhibitors
present (red, violet, orange, green) compared to the distribution in absence of in-
hibitor (blue). c) The average nucleating oligomer size (Nnucl) is constant over a
range of monomer concentrations. A detached oligomer grows in solution by 1.5
monomers on average before converting to a β-nucleus.
3.2.4 Determining the rate of self-replication
We can explain the dependence of rate on the average cluster size on the ﬁbril surface
by introducing a type of two-step nucleation theory that takes into account both
the oligomer growth and structural change [25, 4446]. Nucleation is in general an
activated process that accompanies most ﬁrst-order phase transitions as well as many
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self-assembly phenomena. It involves a growing nucleus of a new phase or structure
that must overcome a free energy barrier in order to grow into a macroscopic phase
at thermodynamic conditions where the emerging phase is stable and the old phase
is only metastable [47,48].
The nucleation process is usually treated by a form of classical nucleation theory
(CNT) where the rate (r) is expressed as a product of an exponential factor and a
frequency prefactor:
r = ρZj exp
(−∆F ∗/kT). (15)
Here ∆F ∗ is the free energy cost of creating the critical nucleus, ρ is the number
density of possible nucleation sites, j the rate or ﬂux with which molecules attach
to the growing nucleus, and Z the Zeldovich factor. This factor signiﬁes that the
probability of a critical nucleus growing into a macroscopic phase is less than one.
Although CNT rarely manages to provide a full quantitative explanation of nucle-
ation phenomena [48], the simple theory in Eq(15) provides a framework for more
accurate theoretical treatments.
In our simulations, nucleation proceeds in multiple steps: monomers adsorb and
oligomerise on the ﬁbril, then the oligomer converts into an intermediate oligomer,
detaches, and then ﬁnally transforms into a β-nucleus. This multi-step process
evolves along two independent reaction coordinates: oligomer size and oligomer
structure. In contrast to the classical picture where a monomer oligomer would
need to reach a certain critical size in order to nucleate, oligomers of all sizes can in
principle convert to a β-nucleus. There exist several paths along the size/structure
landscape and we need to sum over all of them to arrive at the true rate: r =∑
paths ri.
Let us ﬁrst treat a single nucleation path. An oligomer of size N = Ni forms on
the ﬁbril surface by a concomitant adsorption of Ni monomers on some binding site.
This surface oligomer then undergoes structural or conformational change until it
transforms into a Ni-size β-nucleus. We can therefore treat nucleation as a product
of two consecutive activated processes: oligomerisation and conversion. Viewed in
the framework of classical nucleation theory (Eq (15)) the oligomerisation part can
be treated as oligomer growth towards a critical nucleus whereas conversion can be
absorbed in the Zeldovich factor Z(Ni) which again gives the probability that a
critical nucleus actually grows into a new phase. This probability is in our simu-
lations given as a product of a conversion attempt probability ps and a conversion
barrier: Z(Ni) = ps(Ni) exp[−∆Fconv(Ni)/kT ]. Rate of secondary nucleation at a
given oligomer size r(Ni) is then given as:
r(Ni) = ρs ps(Ni) jD e
−∆Folig(Ni)/kT e−∆Fconv(Ni)/kT , (16)
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where ρs is the number density of surface binding sites, jD is a diﬀusion governed ﬂux
of monomers, ∆Folig(Ni) is the free energy cost to make an Ni-size surface oligomer
out of free monomers and Fconv(Ni) is the height of a conversion free energy barrier
to make a Ni-size β-nucleus out of Ni-size surface oligomer. Importantly, we note
that Fconv(Ni) is not dependent on monomer or inhibitor chemical potentials but
only on the interconversion dynamics and thermodynamics of a given oligomer.
Nucleation paths can take other forms from the one outlined in equation (16)
where nucleation proceeds by ﬁrst growth and then structural change. For example
a possible (and in fact frequent) situation is that a surface oligomer of size N = 4
ﬁrst converts into an intermediate oligomer, detaches, and then grows by one or two
monomers in solution before converting to a β-nucleus. This growth in solution,
however, seems to be independent of solution chemical potential (Fig. 11c). We can
then treat this unorthodox path as one of many possibilities on the conversion free
energy landscape of a size 4 oligomer and absorb it into ∆Fconv(N = 4). Therefore,
to sum over all nucleation paths we need simply to sum over all oligomer sizes:
r = ρs jD
∞∑
N=2
ps(N) e
−[∆Folig(N)+∆Fconv(N)]/kT . (17)
Without loss of generality we can rewrite the above sum in terms of a probability
distribution over N by using:
n(N) = Aolig e
−∆Folig(N)/kT ] (18)
Pc(N) = Aconv ps(N) e
−∆Fconv(N)/kT , (19)
where Aolig and Aconv are normalisation constants for the surface oligomer distribu-
tion n(N) and conversion probability distribution Pc(N), respectively. Finally, we
write:
r = B
∞∑
N=2
n(N) · Pc(N), (20)
with B = ρs jD/(Aolig Aconv).
In simulations, the monomer cluster size distribution on the ﬁbril was found to
follow a simple exponential distribution across a range of coverages:
n(N) = (e1/λ − 1)e−N/λ, (21)
where λ is a distribution parameter that increases with monomer and also inhibitor
coverage. As λ is hard to measure, we instead use the average oligomer size on the
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ﬁbril (N), deﬁned as:
N =
∑∞
N=2 n(N) ·N∑∞
N=2 n(N)
, (22)
and evaluated as:
N = 2 +
1
e1/λ − 1 . (23)
We can then rewrite eq(21) as
n(N) =
1
N − 2
(
N − 2
N − 1
)N
. (24)
The charm of the following analysis is that we do not need to know the functional
form of Pconv(N) in order to make progress. We take the total derivative of nucleation
rate with respect to N :
d ln r
dN
=
d lnB
dN
+
d ln
∑∞
N=2 Pc(N) · n(N)
dN
(25)
=
d lnB
dN
+
∑∞
N=2
d
dN
(Pc(N) · n(N))∑∞
N=2 Pc(N) · n(N)
.
We now use the fact that the conversion dynamics are not dependent on the monomer
and inhibitor coverages. Formally, we would write Pc = Pc(N,~, ~µswap, ~pswap), and
N = N(µm, µI , sf , ss), where ~, ~µswap, and ~pswap stand for a collection of interaction
energies, conformation entropy penalties, and swap probabilities between all possible
monomer states, respectively. The only overlapping variables between Pc and N are
ss and sf so we have:
dPc
dN
=
∂Pc
∂ss
∂ss
∂N
+
∂Pc
∂sf
∂sf
∂N
= 0, (26)
because we keep both ss and sf constant throughout our simulation runs. By using
Eq. (24) and Eq. (26) we can now evaluate the expression (25) as:
d ln r
dN
=
d lnB
dN
− 1
N − 2 +
1
(N − 2)(N − 1)
∑∞
N=2N Pc(N) · n(N)∑∞
N=2 Pc(N) · n(N)
=
d lnB
dN
− 1
N − 2 +
Nnucl
(N − 2)(N − 1) , (27)
where Nnucl is the average nucleating oligomer size. In general, this average nucleus
size is weakly dependent on N but in a presaturation regime we ﬁnd it constant in
our simulations (Fig 11c). We can therefore integrate equation(27) over N and get
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the rate of nucleation as:
r =
B
N − 2
[
N − 2
N − 1
]Nnucl
. (28)
In Fig. 11a, we see that this formula makes for a nearly perfect ﬁt to simulation data
with B the only ﬁtted parameter. The rate (r), average oligomer size on the ﬁbril
(N) and the average nucleating oligomer size (Nnucl) are all measured separately.
Additionally, the ﬁt is quite sensitive to the value of Nnucl as outlined by grey
dashed lines in Fig. 11a, making the correspondence between ﬁtted and measured
Nnucl more convincing and valuable.
To recap, we have found that even though our simulated nucleation process
involves several molecular steps and so forms a very complex and multi-dimensional
free energy landscape, we could still predict the self-replication rate with a slight
reinterpretation of the classical nucleation theory. We now turn to the question of
whether crowding on the ﬁbril can ever overcome the inhibitory eﬀect of competing
inhibitors, and ultimately whether we can design inhibitors that are even better at
suppressing self-replication than what we have simulated with our course-grained
model.
3.3 Theoretical lattice model
To investigate whether it is possible that putting inhibitors in solution can speed up
the rate of nucleation we utilise a simple lattice model that captures the interactions
between monomers and inhibitors on the ﬁbril. Because of hard-core repulsions and
tip-to-tip attraction between monomers, a simple Langmuir model proved insuﬃ-
cient to capture the binding of monomers and inhibitors to the ﬁbril. Additionally,
the Langmuir picture cannot account for the crowding eﬀect. Therefore we utilise a
more general albeit still analytical lattice model.
The ﬁbril providesM equivalent and independent binding sites. Each site is able
to accommodate at most two particles. Particles that are bound to the same site
can interact while interactions between separate binding sites are not treated. In
general any combination of monomers and inhibitors can adsorb to a binding site,
that is: sm = 0, 1, 2, sI = 0, 1, 2 subject to a constraint sm + sI <= 2, where sm is
the number of monomers bound on a speciﬁc site, and sI is the number of adsorbed
inhibitors bound to that same site. If sm = 2 we call that a monomer dimer.
The grand partition function for the lattice is Ξ = ξM , where by ξ we denote a
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per-site grand partition function:
ξ =
2∑
sm=0
2∑
sI=0
q(sm, sI) ·
[
eµm/kT
]sm[
eµI/kT
]sI , (29)
where µm, and µI are monomer and inhibitor chemical potentials and q(sm, sI) is a
site partition function that is dependent on the speciﬁc occupancy of both species.
In our simple model, the co-occupancy of a binding site by two particles only shifts
the energy levels inside a particle partition function by a constant energy term that
is given by wmm for the interaction between two monomers, by wII for two inhibitors,
and wmI for the interaction between a monomer and an inhibitor on a binding site.
The possible lattice site partition functions are then given as: q(0, 0) = 1, q(1, 0) =
2 qm, q(0, 1) = 2 qI , q(2, 0) = q2m exp[−wmm/kT ], q(0, 2) = q2I exp[−wII/kT ], and
q(1, 1) = 2 qm qI exp[−wmI/kT ], where qm, and qI are monomer and inhibitor binding
partition functions. Writing out the sum in Eq. (29), we get:
ξ = 1 + 2xm + 2xI + x
2
me
−wmm/kT + x2Ie
−wII/kT + 2xmxIe−wmI/kT , (30)
where we have introduced new shorthand variables xm = qm eµm/kT , and xI =
qI e
µI/kT .
We can now extract all relevant variables from the knowledge of our grand par-
tition function. Average monomer occupancy of a binding site is:
sm =
Nm
M
=
1
M
kT
∂ ln Ξ
∂µm
= xm
∂ ln ξ
∂xm
. (31)
This number (sm ∈ [0, 2)) divided by two gets us monomer coverage θm ∈ [0, 1), so
we have:
θm =
1
2
2xm + 2x
2
me
−wmm/kT + 2xmxIe−wmI/kT
ξ
. (32)
Similarly, we get for the inhibitor coverage:
θI =
1
2
2xI + 2x
2
Ie
−wII/kT + 2xmxIe−wmI/kT
ξ
. (33)
In this theoretical model, the rate of secondary nucleation is captured by the prob-
ability of dimerisation P2. This is the probability of two monomers occupying the
same binding site and is given by:
P2 =
x2me
−wmm/kT
ξ
. (34)
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We can use this probability of dimerisation as a measure for the average cluster size
on the lattice which, as shown in Fig. 11, uniquely determines the rate of nucleation
in our simulations. So we only need P2 in order to ﬁnd how nucleation behaves
under diﬀerent values of inter-protein interactions.
We now by ξ0 = 1 + 2xm + x2me
−wmm/kT and P 02 = x
2
me
−wmm/kT/ξ0 designate the
per-site grand-partition function and dimer probability in the case of no inhibitors:
xI = 0. The most important result of this lattice model is that the probability of
dimerisation will always be smaller if we introduce inhibitors in the solution. For
xI > 0 it always holds that ξ > ξ0 and therefore P2 < P 02 . This indicates that
having particles that compete for the same binding sites on the ﬁbril surface always
drives down the rate of nucleation. No matter the inhibitor design, the eﬀect of
competition will always exceed the possible eﬀect of crowding or other oligomer
growth-inducing interactions on the ﬁbril.
3.3.1 Correspondence to simulation data
We learn the meaning of variables xm and xI by taking the limit wmm, wII , wmI → 0
of monomer coverage (Eq. (32)) and compare it to the Langmuir competitive binding
isotherm θLm:
θm(~w → 0) = xm
1 + xm + xI
, θLm =
cmon/Km
1 + cmon/Km + cI/KI
. (35)
We ﬁnd that xm and xI are simply monomer and inhibitor concentrations, reduced
with respect to their dissociation constants Km and KI . By comparing the binding
curves (Eqs. (32) and (33)) with simulation data, we can estimate the values of
eﬀective binding energies wmm, wIm and wII .
In simulations particles cannot overlap (hard-core repulsion) and monomers have
a favourable tip-to-tip interaction of ss = 4kT strength. We can therefore expect
wmI = wII , and wmm < wmI . We ﬁrst perform a ﬁt of the inhibitor adsorption
data at three diﬀerent surface binding aﬃnities (governed by If ). This way we
vary only KI by keeping wII necessarily constant across the three datasets. We
get a positive eﬀective interaction wII = (2.3 ± 0.2)kT between inhibitors on the
ﬁbril because of repulsive interactions. We then ﬁt the monomer adsorption data
for the case of no attractive interactions between monomers (ss = 0) by setting
wmm0 = wII = 2.3 kT to get Km = (0.22 ± 0.01)mM. Finally, we ﬁt the monomer
adsorption data with the usual cooperative binding interaction ss = 4kT using
previously ﬁtted Km = 0.22mM to ﬁnd wmm = (0.5± 0.3)kT .
We see that our lattice model where only two particles can bind on the same
binding site maps quite well to simulation data in terms of coverage. In principle,
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Figure 12. The binding isotherms are well described by the lattice model. a) We
perform a sweep against a range of inhibitor concentrations (cinh) in the absence of
monomer for three diﬀerent surface interaction strengths (If ). We globally ﬁt these
curves with equation (33) at xm = 0 to ﬁnd the eﬀective interaction between hard
particles as wII = (2.3 ± 0.2)kT. b) We also ﬁt the monomer adsorption data for
ss = 4 kT with equation (32) at xI = 0 and ﬁnd the eﬀective interaction between
cooperatively binding monomers as wmm = (0.5± 0.3)kT.
we could extend the lattice model to include trimers, tetramers and even larger size
oligomers but we ﬁnd those extensions unwieldy and unnecessary because already
dimers are inﬂuenced by the crowding eﬀect.
3.3.2 Crowding and surface pressure
The main motivation for developing this lattice model was the observation of a
crowding eﬀect in simulations, meaning that in addition to depleting the ﬁbril surface
by virtue of competitive binding, inhibitors at the same time accelerate nucleation
by stabilising monomer oligomers on the ﬁbril. This is also what we observe with
this lattice model. When there is repulsion between inhibitors and monomers, we
get an increase in the probability of dimerisation at a given monomer coverage when
inhibitors are present on the ﬁbril (Fig 13a).
In simulations, we explained the rise of nucleation rate at a given coverage by
positing that inhibitors reduce the free energy barrier of oligomer formation. This
reduction is equal to the excess work that has to be provided for an oligomer to
disintegrate. We modelled this excess work as proportional to inhibitor coverage as
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∆∆F (N) = −kTαθI , where α was an undetermined factor. Using the lattice model,
we can model this crowding eﬀect more precisely by evaluating the excess pressure
exerted by bound inhibitors on monomers that are bound into a dimer.
The combined surface pressure of monomers and inhibitors on a lattice is given
by:
φ =
∂(kT ln Ξ)
∂M
= kT ln ξ. (36)
We partition this whole surface pressure into a pure monomer φ0 = kT ln ξ0 and an
excess part φe:
φ = kT ln(ξ0 ∗ ξ/ξ0)
= kT ln ξ0 + kT ln(ξ/ξ0)
≡ φ0 + φe. (37)
For low inhibitor concentration we have ln ξ/ξ0 = sI +O(x3I), or
φe ≈ 2 kT θI . (38)
By doing the same eﬀective coverage transformation in the lattice model as in
simulations, we write:
θLeff = θme
aφe/N− , (39)
where N− = (∂ lnP 02 /∂ ln θ0) is the slope of the blue curve in Fig. 13, and a is a
dimensionless factor. By setting a = 1, and using φc = kT ln ξ/ξ0, all points on
Fig. 13b collapse on the same line. This collapse is almost exact if we use the
φc = kT ln ξ/ξ0 in the eﬀective coverage expression but holds only at low inhibitor
coverages if we approximate φc ≈ 2kTθI as seen in Fig. 13c and Fig. 13d.
So remarkably, we have shown that the expression we used for the eﬀect of
crowding on the free energy of oligomerisation (∆∆Folig)) has a sound footing in
the lattice model where we have been able to analytically arrive at the expression
for the excess pressure that inhibitors impose on the surface. We should note,
however, that this pressure is not a force between particles in the literal sense but
is an eﬀective force that comes from the inﬂuence of monomer-inhibitor interactions
on the distribution of particles on the lattice. We are unsure at this time whether
crowding in our simulations works in a similar implicit way. Intuitively, we might
think that inhibitors physically exert lateral pressure along the ﬁbril surface and
thus keep oligomers from breaking apart. But looking at simulation trajectories
lateral movement along the surface seems rare as most redistribution happens by
desorption-adsorption diﬀusion.
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Figure 13. Crowding in the lattice model. a) Emulating the conditions of our course-
grained simulations, we arrive at the same eﬀect of crowding where bound inhibitors
increase the rate of dimerisation (P2) at a given monomer coverage (θm). b) Taking
inhibitor surface pressure (φe) into account, all data collapses on the same line for
a = 1. c) This collapse is still good if we use φe ≈ 2kTθI but this approximation
(d) gets increasingly worse for higher inhibitor coverages (θI).
But we should note that this model of crowding on a lattice is still largely phe-
nomenological because we still do not really know the meaning of the factor a.
Following the picture that dimers perform work on surface-bound inhibitors, we
would expect a to present the number of binding sites (or lattice volume) released
when a dimer expands against the pressure of surrounding inhibitors so we expect
a ≤ 2 which is well supported by our ﬁt (a = 1). But in the case of no inter-particle
interactions (wmI , wII = 0) for example, we ﬁnd that a has to be zero in order for
the eﬀective coverage expression (Eq. (39)) to work. Also, the collapse to the same
curve in Fig. 13b is very good, but not exact, suggesting that our model of crowding
might need additional enhancements in the future.
3.3.3 Eﬀective inhibitor design
As the lattice model maps quite well to simulation data, we can use the analytical
model to explore parts of parameter space that was not covered in simulations due to
prohibitive computational costs and use it to make some speculations about the most
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Figure 14. Eﬀective inhibitor design. a) Adding attractive interactions with in-
hibitors (violet stands for attraction to monomer: wmI = −2.0kT and dotted for
attraction between inhibitors wII = −2.0kT ) lowers the probability of dimerisation
(P2) in comparison to our basic simulation conditions (green, wmI = wII = 2.3kT ).
b) Monomer coverage (θm) actually increases when adding inhibitors to the solution
if we have monomer-inhibitor attraction (violet) while it is reduced by increasing
inhibitor-inhibitor attraction (dotted). Even by increasing monomer coverage, the
attraction to monomer shows a greater inhibitory power than inter-inhibitor attrac-
tion due to entropy. Graphs are drawn for xm = 0.5 and wmm = 0.5kT .
eﬀective inhibitor design. In simulations, we only have a hard-core repulsion between
inhibitors and monomers wIm = wII = 2.3kT . If we also add some attractive
interactions the lattice model suggests that we further decrease the probability of
dimerisation (P2) at a given set of monomer and inhibitor chemical potentials. This
can be seen with expression (Eq. (34)) where lowering both wIm, and wII increases
the denominator while keeping the numerator constant.
This result, that an attraction between inhibitors enhances inhibition, is per-
haps trivial to understand because this attraction promotes more adsorption of
inhibitors to the surface at a given xI as well as promotes inhibitor dimers that
then compete with monomer dimers. But analytically, we ﬁnd that increasing the
monomer-inhibitor attraction has an even stronger inhibitory eﬀect. The purple
line in Figure 14 (wmI = −2.0kT, wII = 2.3kT ) shows that even though monomer
coverage increases with inhibitor concentration (Fig. 14b) due to cooperation be-
tween adsorbed monomers and inhibitors, the amount of monomer dimers (Fig.
14a) drops even more than for the case of cooperative inhibitor binding (dotted line,
wmI = 2.3kT, wII = −2.0kT ) and deﬁnitely more than for the case of no attractive
interactions with inhibitors (green, wmI = wII = 2.3kT ).
The reason why inter-species attraction provides stronger inhibition than the
attraction between inhibitors is that a state where one monomer and one inhibitor
are bound to the same binding site is entropically more favourable compared to
an inhibitor dimer state as or a monomer dimer state (two times as many micro-
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states). The hierarchy between diﬀerent modes of inhibition: crowding because of
repulsions between inhibitors and monomers, just competition without interactions,
inhibitor cooperative binding, and an attraction between monomers and inhibitors
that limits dimer formation, is preserved across a broad parameter space of diﬀerent
values of xm, xI and wmm. But for binding sites that can accommodate more than
two particles and in diﬀerent geometrical arrangements the eﬀect of inter-species
binding might become less trivial.
To explore this caveat, we performed new simulations with inhibitors that posses
a capacity to bind to each other with the interaction strength II = 4 kT (yellow in
Fig. 15) and with inhibitors that can bind tip-to-tip with monomers with the same
interaction strength sI = 4 kT (dark grey in Fig. 15). Comparing with the red data
points in Fig. 15a new simulation data conﬁrm that increasing attraction between
species makes inhibition of secondary nucleation better, but only very slightly (Fig.
15a).
We do, however, clearly see that increasing II lowers the monomer coverage at
given value of inhibitor concentration compared to the case II = 0 and that in-
creasing sI makes monomer coverage higher (inset of Fig. 15a). So on a graph of
rate against monomer coverage (Fig. 15b), the grey data that stands for monomer-
inhibitor attraction actually falls below the blue line, indicating that at a given
monomer coverage, inhibitors eﬀectively break oligomers apart. But the inhibitory
power should be gauged by how much the nucleation rate drops at given inhibitor
concentration, not how it lowers the nucleation rate at a given monomer coverage
because experimentally or therapeutically the inhibitor concentration is usually the
controlled variable. So overall, in simulations, it is best to design inhibitors with
strong ﬁbril surface aﬃnity but it is even better if inhibitors are capable of cooper-
ative binding to other surface-bound inhibitors or monomers.
Unfortunately, due to loss of access to computing clusters we were not able to
simulate cooperative inhibitor binders for a larger interaction strength which would
tell us if the predictions of the lattice model regarding the stronger inhibition in the
case of binding to monomers are correct. What we can do in the future is to analyse
diﬀerent inhibitor designs on a simulated lattice model of various geometries and
dimensions. If those higher-order lattice models replicate our model with only two
binding sites they could provide design principles that are rigorous and invariant for
diﬀerent distributions of ﬁbril binding sites.
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Figure 15. The eﬀect of inhibitor attraction. a) Both for increasing the attraction
between inhibitors (yellow) and for increasing the monomer-inhibitor attraction on
the ﬁbril surface (grey) the rate of self-replication (r) is slightly decreased at a given
inhibitor concentration (cmon) even as the monomer coverage (θm) actually increases
in the latter case (inset). b) On the rate against coverage graph, the data for inter-
inhibitor attraction (yellow) follows the line of no inhibitor attraction (red) but the
data for monomer-inhibitor attraction lies below the blue line where inhibitor is
absent indicating that at given monomer coverage surface-oligomers made entirely
of monomers tend to be smaller. Inset shows collapse of all datasets on a single
curve, using α = 2N∗ for green, red, and yellow and using α = −0.77N∗ for grey
data.
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4 Conclusions and outlook
In conclusion, we studied the eﬀect of inhibitory particles on the self-replication
pathway that is governed by protein adsorption to the amyloid ﬁbril surface. We
performed extensive computer simulations using a course-grained model where both
proteins and inhibitors are modelled as hard-core spherocylinders with various aniso-
tropic interactions that promote oligomerisation of proteins to micellar-like struc-
tures, binding of proteins and inhibitors to the ﬁbril surface and allow refolding of
proteins to β-rich conformations that promote ﬁbril-like morphologies.
We found that surface-bound inhibitors eﬀectively drive down the rate of sec-
ondary nucleation by competing for the ﬁbril surface with aggregation-prone pro-
teins. But we also get a very signiﬁcant eﬀect where inhibitors actually promote
self-replication at given protein surface coverage. We identiﬁed this eﬀect as macro-
molecular crowding and successfully accounted for it by using a phenomenologi-
cal theory where inhibitors exert a pressure on and marginally stabilise assembled
surface-oligomers. So by perturbing the nucleation pathway with surface-bound in-
hibitors, we actually found that monomer coverage does not uniquely determine the
rate of nucleation as previously believed. Instead, the average size of a surface-bound
oligomer governs the rate of nucleation both in inhibitor's presence and absence. The
formation of a ﬁbril nucleus that characterises ﬁbril self-replication evolves along two
main reaction coordinates, oligomer size and oligomer structure. Inhibitors only in-
ﬂuence the size of oligomers on the surface by shifting the distribution towards larger
oligomers while the structural conversion part of nucleation remains unaﬀected. Us-
ing classical nucleation theory, we found a simple formula that successfully predicts
the rate of self-replication as a function of average surface-oligomer size and the
average nucleating oligomer size even if the underlying free energy landscape of
nucleation appears very complex.
We also studied the nucleation mechanism in the absence of inhibitor. By per-
forming simulations with varying temperature, we reaﬃrmed that the ﬁbril surface
coverage by monomeric protein governs the rate of self-replication. Also, by break-
ing the nucleation process into several major and easily identiﬁable molecular steps,
we identiﬁed the most signiﬁcant or rate-limiting step of nucleation to be the for-
mation and then a partial conversion of a surface-oligomer of appreciable size to
a state where at least three monomers fold into an intermediate state with some
β-sheet content. But if the protein folding kinetics are fast, we found nucleation to
be governed mostly by conversion of detached oligomers to ﬁbril nuclei.
To ascertain whether the crowding eﬀect that promotes oligomerisation can ever
dominate over the competitive binding capacity of inhibitors, we employed an an-
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alytical statistical mechanical model that captures the interactions between bound
species on the ﬁbril surface. We found that the inhibitory eﬀect of competitive bind-
ing always overcomes the eﬀect of crowding so that any ﬁbril-bound particle can
serve as a valuable therapeutic agent that limits the production of toxic oligomers.
Exploring the theoretical model further and comparing with simulation data, we
found that the best design for an inhibitory particle would involve a very strong
aﬃnity to ﬁbril surface as well as attractive interactions to both to surface-bound
monomers and inhibitors.
Especially this inhibitor-monomer attraction that promotes binding into an al-
ternative chain should be explored further in the future as it might slow down both
the self-replication catalysed by the ﬁbril surface as well as spontaneous nucleation
in solution because they are both governed by oligomerisation in the same way.
We can envision that a strong attraction between monomers and inhibitors might
stabilise larger oligomers. But at the same time, only a small part of those larger
oligomers would participate in the conversion to ﬁbril nucleus. It is likely that the
possible (non-)inhibitory eﬀect of alternative chain binding would largely depend on
the speciﬁc geometry of co-oligomers, both on the surface and in solution.
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5 Raz²irjeni povzetek v slovenskem jeziku
Proteinski ali amiloidni ﬁbrili so podolgovate nitaste strukture, ki nastanejo z agre-
gacijo normalno topnih proteinov. So dominantna oblika proteinskih agregatov in
so vpleteni v razvoj ve£ kot 50 £love²kih bolezni, ki so trenutno neozdravljive in
postajajo vse bolj problemati£ne zaradi staranja prebivalstva in sodobnega na£ina
ºivljenja. Med njimi so Parkinsonova bolezen, diabetes tipa II in zlasti Alzheimer-
jeva bolezen, ki je odgovorna za do 80% vseh primerov demence.
Agregacijska reakcija je zelo heterogena in vsebuje mnogo molekularnih korakov,
ki jih lahko reduciramo na le nekaj poglavitnih. Prvi pomemben korak je spontana
oziroma primarna nukleacija v razstopini s katero iz topnih delno zvitih proteinov
nastanejo prva jedra ﬁbrilov. Tak²na jedra nato rastejo (elongacija) z vezavo pro-
teinov na oba konca eno-dimenzionalne ﬁbrilarne strukture do makroskopskih dimen-
zij (reda µm). Ta dva procesa sta dovolj za opis zgodnje faze agregacijske reakcije,
vendar se po oblikovanju makroskopskih ﬁbrilov za£ne proces samo-replikacije. V
tem procesu povr²ina ºe izraslih ﬁbrilov katalizira nastanek novih ﬁbrilnih jeder, kar
vodi do eksponentne rasti ²tevila in mase ﬁbrilov in do hitrega ²irjenja vpliva amiloid-
nih bolezni. Ta avto-kataliti£ni proces je ²e posebej pomemben pri Alzheimerjevi
bolezni, saj je glavni vir toksi£nih oligomerjev, ki povzro£ajo nevronsko smrt. To
so amorfni proteinski agregati, ki ²e nimajo lastnosti ﬁbrilov, ampak se lahko pre-
strukturirajo v ﬁbrilna jedra.
V tej magistrski nalogi se ukvarjamo z vpra²anjem, kako upo£asniti ali celo zaus-
taviti proces samo-replikacije z delci, ki jih v tej nalogi imenujemo inhibitorji. Ti
delujejo tako, da tekmujejo z amiloidnimi proteini za vezavna mesta na povr²ini
in tako prepre£ujejo, da bi se proteini na povr²ini sre£ali in posledi£no agregirali.
Tega vpra²anja se lotimo s pomo£jo minimalnega ra£unalni²kega modela, ki je ºe
bil uspe²no uporabljen za opis in razlago spontane nukleacije v razstopini in samo-
replikacije na povr²ini. Na²e Monte Carlo simulacije zajamejo dejstvo, da lahko
protein obstaja v najmanj dveh stanjih: v topnem, delno zvitem stanju, v katerem
se protein lahko zdruºuje v micelarne skupke oziroma oligomere in v stanju z niºjo
konformacijsko entropijo, z ve£ β strukture, ki se lahko lateralno veºe v podol-
govate ﬁbrile. Vse interakcije so usmerjene in anizotropne, delce modeliramo kot
sferocilindre s trdo sredico. Tako proteini v topnem stanju kot inhibitorji se lahko
veºejo na povr²ino ºe obstoje£ega ﬁbrila, ki nam v simulaciji sluºi kot kataliti£na
povr²ina. Simulacijo pripravimo tako, da glede na izbran kemijski potencial pro-
teinov in inhibitorjev simulacijsko ²katlo naselimo z razstopljenimi delci in da na
sredino ²katle vstavimo ºe formiran ﬁbril, ki ne more rasti, ampak deluje kot katali-
ti£na povr²ina. Nato pustimo, da se delci veºejo in zapu²£ajo povr²ino, dokler ta ne
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doseºe dinami£nega ravnovesja z razstopino. Nato vklju£imo moºnost, da proteini
na diskreten na£in spremenijo vsebnost β sekundarne strukture. Nukleacijo dobimo,
ko se vsaj dva proteinska delca veºeta v oligomer s polno β strukturo.
Najprej preu£imo mehanizem samo-replikacije v odsotnosti inhibitorja. Repro-
duciramo rezultate prej²nje ²tudije in analiziramo nove simulacije, kjer spreminjamo
temperaturo pri konstantni koncentraciji proteinov. Z zdruºitvijo osnovnih simu-
lacij, kjer spreminjamo kemijski potencial proteinov, in novih temperaturnih simu-
lacij potrdimo, da ima pokritost povr²ine s proteini klju£no vlogo pri avto-katalizi
ﬁbrilov. Zaºenemo tudi ve£ simulacij pri razli£nih hitrostih dinamike zvijanja pro-
teinov. Ugotovimo, da je najpo£asnej²i molekularni korak v na²i avto-kataliti£ni
reakciji tvorba dovolj velikega oligomera na povr²ini ﬁbrila, ki je ºe delno zvit in
ima ºe nekaj β-list strukture. Po drugi strani, ob pogoju da je kinetika zvijanja
proteinov hitra, najdemo najpo£asnej²i in tako najpomembnej²i korak v nukleaciji
v delni pretvorbi odcepljenega, v razstopini plavajo£ega, oligomera v strukturo, kjer
ima en del oligomera ºe pre£no β strukturo, ki je zna£ilna za odrasle ﬁbrile.
Nato se lotimo preu£evanja vpliva inhibitornih delcev na mehanizem nukleacije.
Ugotovimo, da na povr²ino vezani inhibitorji u£inkovito zmanj²ajo hitrost samo-
replikacije na na£in, da s proteini tekmujejo za ista vezavna mesta, ki jih zasedejo in
tako zmanj²ajo pokritost povr²ine s proteini. Ve£ja kot je vezavna energija inhibitor-
jev na povr²ino, bolj²a je inhibicija pri dolo£eni koncentraciji inhibitorjev. Hkrati pa
dobimo tudi zelo pomemben pojav gne£enja, kjer inhibitorji dejansko pospe²ujejo
nukleacijo pri dolo£eni pokritosti povr²ine z amiloidnimi proteini. Ta pojav gne£enja
pojasnimo s fenomenolo²ko teorijo, kjer inhibitorji izvajajo povr²inski tlak na vezane
proteine v njihovi okolici in marginalno stabilizirajo ºe sestavljene oligomere. Torej s
perturbacijo nukleacijske poti z inhibitorji ugotovimo, da pokritost ﬁbrilne povr²ine z
agregacijskimi proteini navsezadnje ne dolo£a hitrosti samo-replikacije na edinstven
na£in, kot je bilo do sedaj sprejeto. S pomo£jo teorije vpeljemo efektivno pokri-
tost povr²ine, ki je renormalizirana glede na vpliv inhibitorjev in pravilno napove
hitrost samo-replikacije pri vseh kombinacijah kemijskih potencialov proteinov in
inhibitorjev.
Nato poi²£emo ²e en deskriptor hitrosti samo-replikacije, ki velja v odsotnosti
kot tudi prisotnosti inhibitorjev na povr²ini in ga najdemo v povpre£ni velikosti
povr²inskih oligomerov. Oblikovanje oligomera oziroma ﬁbrilnega jedra, ki je ter-
modinamsko stabilno, poteka preko vsaj dveh reakcijskih spremenljivk: velikosti
oligomera in njegove strukture v smislu vsebnosti β sekundarne strukture. In-
hibitorji na povr²ini vplivajo le na oligomerizacijo proteinov na na£in, da potisnejo
porazdelitev oligomerov na ﬁbrilni povr²ini k ve£jim oligomerov, ampak ne vplivajo
na konformacijski del preobrazbe skupkov proteinov v ﬁbrilno jedro. Z uporabo
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in reinterpretacijo klasi£ne teorije nukleacije smo kljub zelo kompleksni nukleacijski
poti izlu²£ili preprosto formulo, ki uspe²no napove povezavo med hitrostjo samo-
replikacije na eni strani in povpre£no velikostjo na povr²ino vezanega proteinskega
oligomera ter povpre£no velikostjo ﬁbrilnega jedra na drugi strani.
Nato smo raziskali, ali lahko vpliv gne£enja molekul na povr²ini kadarkoli pre-
vlada nad vplivom tekmovanja proteinov in inhibitorjev za ista vezavna mesta.
Razvijemo statisti£no-mehanski mreºni model, ki zraven obi£ajne vezave obeh vrst
delcev na povr²ino upo²teva tudi interakcije med vezanimi delci in posledi£no zelo
dobro zajame obna²anje vezavnih izoterm obeh delcev v simulacijah. Izkaºe se, da
tekmovalni efekt za ista vezavna mesta vedno prevlada nad gne£enjem, tako da lahko
katerikoli delec, ki ima moºnost vsidranja na ﬁbrilno povr²ino, sluºi v medicinske
namene. Vseeno pa so nekatere interakcije med vezanimi delci bolj u£inkovite v
inhibiciji samo-replikacije kot druge. Teoreti£ni mreºni model lahko uporabimo,
da razi²£emo smernice za oblikovanje interakcij s £im bolj u£inkovitim inhibici-
jskim u£inkom. Ugotovimo, da privla£ne interakcije med inhibitorji na povr²ini
kot tudi med vezanimi proteini in inhibitorji oja£ajo inhibicijski u£inek. Prve zato,
ker promovirajo kooperativno vezavo inhibitorjev in torej pri dolo£eni koncentraciji
inhibitorjev v razstopini dobimo ve£ vezav inhibitorja na povr²ino. Zanimivo pa
privla£na interakcija med inhibitorji in proteini celo bolj u£inkovito inhibira katal-
iti£ni proces na povr²ini, £eprav se ²tevilo adsorbiranih proteinov pod vplivom in-
hibitorjev celo pove£a in ne zmanj²a. Tak²na privla£na interakcija namre£ spodbuja
vezavo v me²ane oligomere, ki so delno sestavljeni iz proteinov in delno iz inhibitor-
jev. Ti oligomeri so sicer v povpre£ju ve£ji in entropi£no bolj zaºeljeni, ampak ima
le manj²i del oligomera moºnost zvitja v β strukture, tako da je nukleacija me²anega
oligomera veliko po£asnej²a oziroma manj verjetna.
V prihodnje bi bilo vredno raziskati, kako geometrija razli£nih mreºnih modelov
vpliva na zaklju£ke na²e ²tudije glede oblikovanja interakcij med inhibitorji in ostal-
imi na povr²ino vezanimi proteini, da bi se inhibicijska mo£ pove£ala. Lahko bi se
namre£ zgodilo, da se vpliv me²anih oligomerov razli£no obna²a pri oligomerizaciji
v eni, dveh ali treh dimenzijah in pri razli£nem ²tevilu interakcijskih sosedov.
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